MX2022003699A - Composiciones y métodos relacionados para bloquear la localización secundaria de dextranos manosilados y otros ligandos cd206. - Google Patents
Composiciones y métodos relacionados para bloquear la localización secundaria de dextranos manosilados y otros ligandos cd206.Info
- Publication number
- MX2022003699A MX2022003699A MX2022003699A MX2022003699A MX2022003699A MX 2022003699 A MX2022003699 A MX 2022003699A MX 2022003699 A MX2022003699 A MX 2022003699A MX 2022003699 A MX2022003699 A MX 2022003699A MX 2022003699 A MX2022003699 A MX 2022003699A
- Authority
- MX
- Mexico
- Prior art keywords
- mannosylated
- blocking
- backbone
- dextrans
- ligands
- Prior art date
Links
- 229920002307 Dextran Polymers 0.000 title abstract 3
- 230000000903 blocking effect Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000003446 ligand Substances 0.000 title 1
- 230000004807 localization Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- -1 dextran backbone compound Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
- A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0495—Pretargeting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962908136P | 2019-09-30 | 2019-09-30 | |
| PCT/US2020/053604 WO2021067479A1 (en) | 2019-09-30 | 2020-09-30 | Compositions and related methods for blocking off-target localization of mannosylated dextrans and other cd206 ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022003699A true MX2022003699A (es) | 2022-07-13 |
Family
ID=75337533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022003699A MX2022003699A (es) | 2019-09-30 | 2020-09-30 | Composiciones y métodos relacionados para bloquear la localización secundaria de dextranos manosilados y otros ligandos cd206. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210145989A1 (https=) |
| EP (1) | EP4021459A4 (https=) |
| JP (1) | JP7599727B2 (https=) |
| CN (1) | CN115151264B (https=) |
| CA (1) | CA3155675A1 (https=) |
| MX (1) | MX2022003699A (https=) |
| WO (1) | WO2021067479A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3192041A1 (en) * | 2020-08-21 | 2022-02-24 | Resolute Science, Inc. | Compositions and methods for targeting tumor-associated macrophages |
| EP4472643A1 (en) * | 2022-02-04 | 2024-12-11 | Navidea Biopharmaceuticals, Inc. | Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking |
| US20230302041A1 (en) * | 2022-03-25 | 2023-09-28 | Navidea Biopharmaceuticals, Inc. | Competitive Self-Blocking with Unlabeled Manocept Imaging Agents |
| CN114894698B (zh) * | 2022-04-15 | 2023-02-03 | 广东省第二人民医院（广东省卫生应急医院） | MDSCs在再生障碍性贫血诊断和/或分型中的应用 |
| EP4554984A1 (en) * | 2022-07-13 | 2025-05-21 | Navidea Biopharmaceuticals, Inc. | Mannosylated amine dextran drug delivery vehicles with degradable disulfide/carbonate linkers targeting payloads to cd206 expressing cells |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4624046A (en) * | 1982-01-04 | 1986-11-25 | Fairchild Camera & Instrument Corp. | Oxide isolation process for standard RAM/PROM and lateral PNP cell RAM |
| US4624846A (en) * | 1983-07-29 | 1986-11-25 | Immunomedics, Inc. | Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles |
| JP3582234B2 (ja) * | 1996-05-20 | 2004-10-27 | ニプロ株式会社 | ＩｇＡ腎症特異的フィブロネクチン断片、その検出方法およびキット |
| EP1178838B1 (en) * | 1999-05-14 | 2004-09-29 | The Regents of the University of California | Macromolecular carrier based on dextran for drug and diagnostic agent delivery |
| US20050169883A1 (en) * | 2002-05-06 | 2005-08-04 | Prestwich Glenn D. | Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents |
| AU2003267872A1 (en) * | 2002-05-06 | 2003-11-11 | University Of Utah Research Foundation | Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents |
| US20080193372A1 (en) * | 2004-02-10 | 2008-08-14 | Barnes-Jewish Hospital | Efficacy and Safety of Targeted Particulate Agents with Decoy Systems |
| JP4543860B2 (ja) * | 2004-09-30 | 2010-09-15 | 株式会社島津製作所 | 試料の解析方法 |
| US20080004237A1 (en) * | 2006-02-23 | 2008-01-03 | Tam Joemy C | Polysacchocride prodrug of 5-fluorouracil (5-FU) with enhanced target specificity for galectin-3 expressing cancers |
| WO2012171035A1 (en) * | 2011-06-10 | 2012-12-13 | University Of Washington Through Its Center For Commercialization | Carbohydrate-based compositions and methods for targeted drug delivery |
| CN114377143A (zh) * | 2013-07-22 | 2022-04-22 | 康德乐健康414有限责任公司 | 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒 |
| WO2016011419A1 (en) * | 2014-07-17 | 2016-01-21 | Ohio State Innovation Foundation | Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis |
| CA2955438C (en) * | 2014-07-17 | 2024-07-02 | Ohio State Innovation Foundation | DEXTRANE CONJUGATES TO TARGET MACROPHAGES AND OTHER CELLS EXPRESSING THE D-MANBOSE BINDING TYPE C LECTIN RECEPTOR |
| WO2016118188A1 (en) * | 2015-01-21 | 2016-07-28 | Navidea Biopharmaceuticals, Inc. | Compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells |
| MX2019004029A (es) * | 2016-10-07 | 2019-09-27 | Navidea Biopharmaceuticals Inc | Compuestos y metodos para diagnosis y tratamiento de infecciones virales. |
| CA3064277A1 (en) * | 2017-05-19 | 2018-11-22 | Navidea Biopharmaceuticals, Inc. | Cd206+ macrophage-specific molecular imaging probe compositions and methods and the noninvasive quantification of arterial wall macrophage infiltration in humans |
| WO2019018815A1 (en) * | 2017-07-21 | 2019-01-24 | Navidea Biopharmaceuticals, Inc. | USE OF 99MTC-TILMANOCEPT AND ASSOCIATED MOLECULAR CONSTRUCTS FOR THE IDENTIFICATION AND DIAGNOSIS OF MALIGNANT TUMORS, AND FOR THE MONITORING OF ANTI-TUMOR THERAPEUTIC INTERVENTIONS |
-
2020
- 2020-09-30 US US17/039,409 patent/US20210145989A1/en active Pending
- 2020-09-30 CN CN202080083041.5A patent/CN115151264B/zh active Active
- 2020-09-30 JP JP2022519804A patent/JP7599727B2/ja active Active
- 2020-09-30 WO PCT/US2020/053604 patent/WO2021067479A1/en not_active Ceased
- 2020-09-30 EP EP20872002.9A patent/EP4021459A4/en active Pending
- 2020-09-30 CA CA3155675A patent/CA3155675A1/en active Pending
- 2020-09-30 MX MX2022003699A patent/MX2022003699A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3155675A1 (en) | 2021-04-08 |
| WO2021067479A1 (en) | 2021-04-08 |
| US20210145989A1 (en) | 2021-05-20 |
| JP7599727B2 (ja) | 2024-12-16 |
| CN115151264B (zh) | 2024-03-12 |
| JP2022550174A (ja) | 2022-11-30 |
| EP4021459A4 (en) | 2023-09-27 |
| EP4021459A1 (en) | 2022-07-06 |
| CN115151264A (zh) | 2022-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022003699A (es) | Composiciones y métodos relacionados para bloquear la localización secundaria de dextranos manosilados y otros ligandos cd206. | |
| PH12021552482A1 (en) | Compounds targeting prmt5 | |
| EP4272818A3 (en) | Thrombolytic agent for the treatment of thromboembolism | |
| EP4707394A3 (en) | Rnai agents for hepatitis b virus infection | |
| MX2009008439A (es) | Nuevos inhibidores de la replicacion del virus de hepatitis c. | |
| PH12020550065A1 (en) | Hepatitis b antiviral agents | |
| ME01600B (me) | MIKRORNK (MIRNK) MIR-21 ZA DIJAGNOZU l TERAPEUTSKE SVRHE | |
| WO2005117954A3 (en) | Compositions and methods for treatment of neovascular diseases | |
| WO2009132238A3 (en) | Ido inhibitors | |
| WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
| MX2022010748A (es) | Metodos para tratar la glomeruloesclerosis segmentaria focal dependiente de apolipoproteina l1 (apol-1). | |
| WO2008005084A3 (en) | Methods to prevent and treat diseases | |
| MX2024003772A (es) | Compuestos de imidazopiridazina inhibidores de il-17. | |
| MX2021007738A (es) | Derivados de (piridin-2-il)amina como inhibidores de tgf-beta r1 (alk5) para el tratamiento de cancer. | |
| MX2022010258A (es) | Composiciones y métodos para tratar la lesión renal. | |
| AU2018306329A8 (en) | Methods of protecting vascular integrity induced by targeted radiation therapy | |
| WO2020160453A8 (en) | Modulators of yap1 expression | |
| WO2011153458A3 (en) | Compositions and methods for inhibition of or treatment of dengue virus infection | |
| EP4245372A3 (en) | Hbv inhibitor and use thereof | |
| WO2008030605A3 (en) | Herv group ii viruses in lymphoma and cancer | |
| WO2021242844A8 (en) | Grk2 inhibitors and uses thereof | |
| ZA202102241B (en) | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety | |
| MX2025013372A (es) | Inhibidores de gsk3\03b1 y metodos de uso de estos | |
| MX2023014898A (es) | Terapia combinada anti-vhc ventajosa. | |
| WO2009148600A3 (en) | Deuterated lysine-based compounds |